GUANZE MEDICAL (02427) announced its annual results for the period ending December 31, 2025. Revenue amounted to RMB88.45 million, representing a decrease of 43.2% compared to the previous year. The loss attributable to the company's owners was RMB29.72 million, a significant shift from a profit of RMB17.20 million in the same period last year. The basic loss per share was RMB0.03. The decline in total annual revenue was primarily due to reduced sales of medical imaging film products and medical imaging cloud services.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments